Evidence map›Paper›PMID 39063132›Full record

ArticleInternational journal of molecular sciences2024

[

Yasmin K Sandhu, Harman S Bath, Jasmine Shergill, Christopher Liang, Amina U Syed, Allyson Ngo, Fariha Karim, Geidy E Serrano, Thomas G Beach, Jogeshwar Mukherjee

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Assessment of [Biomolecules · 2025
    Article
  4. [Synapse (New York, N.Y.) · 2025
    Article
  5. Reduction in [Brain research · 2025
    Article
  6. Review
  7. [Biomolecules · 2025
    Article
  8. Article
  9. Evaluation of [Receptors (Basel, Switzerland) · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yasmin K SandhuPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Harman S BathPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0002-4759-8022
Jasmine ShergillPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Christopher LiangPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Amina U SyedPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Allyson NgoPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0002-6993-9131
Fariha KarimPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Geidy E SerranoBanner Sun Health Research Institute, Sun City, AZ 85351, USA.
Thomas G BeachBanner Sun Health Research Institute, Sun City, AZ 85351, USA.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0000-0003-1009-877X

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI RICHARD A. VAN ETTEN · 1994 to 2026
$57.9M
PET Imaging Agents for Nicotinic a4b2 ReceptorsR01AG029479 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MUKHERJEE, JOGESHWAR · 2007 to 2017
$2.6M
Novel Tau-Targeted Radiohalogenated Agents for Alzheimer's DiseaseR01AG077700 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Jogeshwar Mukherjee · 2024 to 2026
$2.1M
Evaluation of Monoamine Oxidase-A as a New Biomarker for Alzheimer's DiseaseR21AG079189 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MUKHERJEE, JOGESHWAR · 2022 to 2022
$432k
NCI NIH HHS P30 CA062203NIA NIH HHS R01 AG029479NIA NIH HHS R01 AG077700NIA NIH HHS R21 AG079189
6 · The paper itself

Abstract

The diagnostic value of imaging Aβ plaques in Alzheimer's disease (AD) has accelerated the development of fluorine-18 labeled radiotracers with a longer half-life for easier translation to clinical use. We have developed [

Indexed as

Alzheimer DiseaseFluorine RadioisotopesHippocampusPlaque, AmyloidPositron Emission Tomography Computed TomographyAgedAged, 80 and overAnimalsAutopsyBrainDisease Models, AnimalFemaleHumansMaleMiceMice, Transgenic1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-oneFluorine-18Fluorine RadioisotopesPyridinesPyrrolidinonesRadiopharmaceuticals[18F]flotaza5xFAD transgenic miceAlzheimer’s diseasehippocampushuman Aβ plaquesPET imaging

Identifiers

PMID39063132
PMCPMC11277463

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.